USPTO serial 79250595
NEUROVIVE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 28, 2020
- Examiner
- DIBLE, JONATHON I
- Law office
- TMO LAW OFFICE 111
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NEUROVIVE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Paul F. Kilmer
Paul F. Kilmer HOLLAND & KNIGHT LLP800 17th Street, NWSuite 1100Washington, DC 20006Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Acetates for pharmaceutical purposes; acids for pharmaceutical purposes; adjuvants for medical purposes; aldehydes for pharmaceutical purposes; alginates for pharmaceutical purposes; amino acids for medical purposes; amino acids for veterinary purposes; antibiotics; antidiabetic pharmaceuticals; food supplements, namely, antioxidant pills; food supplements, namely, antioxidants; antitumor drugs in the nature of tumor suppressing agents; appetite suppressant pills; appetite suppressants; appetite suppressants for medical purposes; appetite suppressants for veterinary purposes; bacterial preparations for medical use; bacterial preparations for veterinary use; bacteriological culture mediums; bacteriological preparations for medical purposes; bacteriological preparations for medical use; bacteriological preparations for veterinary purposes; bacteriological preparations for veterinary use; biological preparations for medical purposes for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; biological preparations for the treatment of cancer; biological tissue cultures for medical purposes; biological tissue cultures for veterinary purposes; biological tissues for implantation being implants comprising living tissue; bouillons for bacteriological cultures; cachets being capsules sold empty for pharmaceutical preparations; capsules sold empty for pharmaceutical preparations; castor oil for medical purposes; cellulose ethers for pharmaceutical purposes; chemical preparations for medical purposes, namely, for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; chemical preparations for pharmaceutical purposes, namely, for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; chemicopharmaceutical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; cytostatic drugs for medical purposes; decoctions for pharmaceutical purposes, namely, for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; dental wax; diagnostic biomarker reagents for medical purposes; diagnostic biomarker reagents for veterinary purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical use; diagnostic preparations for veterinary use; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic radiopharmaceutical preparations; dietary supplements for animals; dietary supplements for humans; dietetic food and substances adapted for medical or veterinary use, namely, food for human and animal babies; dietetic food and substances adapted for medical or veterinary use; dietetic substances adapted for medical use, namely, food for babies; digestive enzymes being dietary supplements; disinfectants; drugs for medical purposes in the nature of medical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations, namely, elixirs for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; enzyme dietary supplements; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; esters for pharmaceutical use; ethers for pharmaceutical purposes; ferments for pharmaceutical purposes; ferments for pharmaceutical use; ferments for veterinary purposes; ferments for veterinary use; food esters for pharmaceutical purposes; formic aldehyde for pharmaceutical purposes; formic aldehyde for veterinary purposes; ] fungicides, herbicides; [ in vitro diagnostic preparations for medical use; skin lotions for medical purposes; skin lotions for pharmaceutical purposes; material for stopping teeth; material for stopping teeth, dental wax; media for bacteriological cultures; medical and veterinary preparations and products for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medical preparations for slimming purposes; medical vaccines; medicated animal feed; medicinal drinks; medicinal infusions for treating metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medicinal oils; medicines and pharmaceutical preparations for neurosurgical conditions, brain damage, and neurological operations; medicines and pharmaceutical preparations for neurosurgical conditions, brain damage and brain operations; medicines and pharmaceutical preparations for the treatment of neurosurgical conditions, brain damage, brain operations, and other physical and neurological ailments of the brain; medicines and pharmaceutical preparations for the treatment of neurosurgical conditions, namely, for brain damage and for use in brain operations and other physical and neurological ailments of the brain; medicines and pharmaceutical preparations for use as immunosuppressive agents; medicines and pharmaceutical preparations for use as immunosuppressive agents in organ transplants or other medical and clinical uses of immunosuppressive agents; medicines and pharmaceutical preparations for use as immunosuppressive agents for organ transplants; medicines and pharmaceutical preparations for neurological conditions within the area of neurological intensive care; medicines for human purposes in the nature of medicinal preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; mixed biological preparations for medical purposes, namely, for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; nutritional supplements; nutritional supplements for livestock feed; medicated ointments for medical purposes, namely, for treating dermatological conditions; pharmaceutical and veterinary preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical and veterinary preparations, namely, medicines and pharmaceutical preparations for the treatment and prevention of acute and chronic neurological illnesses and conditions; pharmaceutical and veterinary preparations, namely, medicines and pharmaceutical preparations for acute and chronic neurological illnesses and conditions and for preventative treatment; pharmaceutical drugs in the nature of pharmaceutical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and other ] preparations for destroying vermin; fungicides and herbicides [ ; pharmaceutical preparations and substances for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human use for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations for medical purposes and veterinary purposes, namely, for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations for medical use consisting of a cyclosporin as active agent and diluents to treat stroke, traumatic brain or spinal cord injury, and other acute or chronic neurological and neurosurgical conditions; pharmaceutical preparations for medical use consisting of a cyclosporin or another cyclophilin inhibitor as active agent and diluents to treat stroke, traumatic brain or spinal cord injury, and other acute or chronic neurological and neurosurgical conditions; pharmaceutical preparations for skin care; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria in the nature of antibacterial pharmaceuticals; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumors; pharmaceutical preparations for the treatment of viral diseases in the nature of antivirals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating heatstroke; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for use as immunosuppressive agents; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for neurological conditions within the area of neurological intensive care; pharmaceutical preparations for the prevention of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medical and veterinary preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; phosphates for pharmaceutical purposes; phosphates for veterinary purposes; medical plasters; medical dressings; potassium salts for medical purposes; potassium salts for veterinary purposes; preparations for destroying vermin; quinine for medical purposes; quinine for veterinary purposes; mineral salts for medical purposes; sanitary preparations for medical purposes; sanitary preparations for veterinary purposes; slimming pills being medical preparations for slimming purposes; sodium salts for medical purposes; sodium salts for veterinary purposes; sulfonamide preparations; tinctures being medicinal drinks for medical purposes; tinctures being medicinal drinks for veterinary purposes; tonics being medicinal drinks; tonics being medicinal drinks for medical use; tonics being medicinal drinks for veterinary use; vaccines; vaccines for human use; veterinary vaccines; drugs and pharmaceutical preparations for acute and chronic neurological diseases and conditions including preventive treatment; the aforementioned rare diseases consisting of Alpers Disease, ALS (Amyotrophic Lateral Sclerosis), Autism, Barth syndrome, Complex I Deficiency (NADH dehydrogenase deficiency), Complex II Deficiency (NADH-CoQ reductase deficiency), Complex III Deficiency (Ubiquinone-cytochrome c oxidoreductase deficiency), Complex IV Deficiency/COX Deficiency, Complex V Deficiency (ATP synthase deficiency), CPEO (Chronic Progressive External Ophthalmoplegia Syndrome), Friedreich's ataxia (FRDA or FA), KSS (Kearns-Sayre Syndrome), Lactic Acidosis, Leigh Disease or Syndrome (Subacute Necrotizing Encephalomyelopathy), LHON (Leber's hereditary optic neuropathy), MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Strokelike Episodes), MERRF (Myoclonic Epilepsy and Ragged-Red Fiber Disease), MIDD (Maternally Inherited Diabetes and Deafness), Mitochondrial Myopathy, MNGIE (Myoneurogastointestinal Disorder and Encephalopathy, NARP) (Neuropathy, Ataxia, and Retinitis Pigmentosa), Neurodegenerative disorders associated with Parkinson's, Alzheimer's or Huntington's disease, Pearson Syndrome, Pyruvate Carboxylase Deficiency, Pyruvate Dehydrogenase Deficiency, POLG Mutations ] | ACTIVE | — |
| 009 | Chromatography apparatus for laboratory use; DNA chips; electrodes for laboratory research | ACTIVE | — |
| 010 | [ Blood testing apparatus; electrodes for medical use; probes for medical purposes; probes for veterinary purposes; electrodes for veterinary use, namely, medical electrodes ] | SECTION 7(e) - CANCELLED | — |
| 042 | [ Analysis of human tissues for medical research; bacteriological analysis and consultation relating thereto; biochemical research; biological analysis; scientific biological laboratory services; biological research and analysis; biological research, medical research and clinical research in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; biological sample analysis for scientific and medical research purposes; biological samples, blood or other bodily fluids analysis services for scientific and medical research purposes; biotechnology research; blood analysis services; blood analysis services for scientific and medical research purposes; chemical analysis and research; chemical research and analysis services; chemistry consultancy services; clinical research in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; clinical research and trials for others in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; scientific research, namely, conducting clinical trials for others; conducting clinical trials being scientific research for others; conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; conducting early evaluations in the field of new pharmaceuticals; ] consultancy in the field of cosmetics, namely, consultancy in connection with the quality inspection, research and development of cosmetic products and medicated cosmetic products; [ consultancy in the field of sanitary research for medical purpose; consultancy in pharmaceutical, pharmacogenetics, medical chemistry, and veterinary research; consultancy services in the field of biological research; consultancy services in the field of biotechnology; consulting on pharmacogenetics in the nature of pharmaceutical consultation; ] cosmetics research; cosmetics research and analysis services; cosmetics research services and laboratory analysis services in the field of cosmetics; design and development of computer hardware and software; [ design and development of diagnostic apparatus and instruments for medical use; design and development of medical diagnostic apparatus and instruments; development, testing and consultancy services in the fields of biotechnology research, pharmaceutical research, medical research, veterinary medicine research, chemistry research, biology research, and pharmacogenetics research; DNA analysis for scientific and medical research purposes; drug and pharmaceutical discovery, testing and development services; drug discovery services; industrial analysis and research services in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; laboratory research services relating to pharmaceuticals; medical and veterinary product research and development and consultancy related thereto; medical laboratory services; medical research; pharmaceutical product evaluation; pharmaceutical products development; pharmaceutical research and development; pharmaceutical research services; providing information in connection with all the aforementioned services; providing medical and veterinary testing services in the field of research relating to medicines, drug discovery, drug development and drug screening, and consultancy related thereto; research and development in the field of biotechnology; biochemical research and development of microorganisms and cells; research and development in the pharmaceutical and biotechnology fields; scientific research and development services; research and testing in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; research of pharmaceuticals; research relating to biotechnology; research relating to pharmaceuticals; research, development, and testing services, and consultancy related thereto, in the fields of biotechnology products, pharmaceutical products, sanitary products, medical products, veterinary products, chemistry products, biology products, and pharmacogenetics products; research, development, and testing services, and consultancy related thereto, in the fields of biotechnology, pharmaceuticals, sanitary products, chemistry, biology and pharmacogenetics; research, development, testing and consultancy services in the fields of biotechnology products, pharmaceutical products, medical products, sanitary products, veterinary products, chemistry products, biology products, and pharmacogenetics products; research, development, testing, scientific consultancy services in the fields of biotechnology products, pharmaceutical products, medical products, sanitary products, veterinary products, chemistry products, biology products, and pharmacogenetics products; research in the field of environmental protection; research, testing and development of sanitary, pharmaceutical, medical, medicinal chemical, veterinary preparations; research, testing and development of biotechnical, biological preparations; research, testing and development in the field of diagnostic preparations; research, testing and development of diagnostic preparations for medical purpose; scientific analysis in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; scientific and technological services, namely, scientific research, analysis and testing in the fields of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction, and research and design relating thereto; scientific laboratory services; scientific research; ] scientific research relating to cosmetics [ ; testing of pharmaceuticals; blood toxicity analysis; toxicity testing in the nature of drug screening for research purposes; veterinary laboratory services; the aforementioned rare diseases consisting of Alpers Disease, ALS (Amyotrophic Lateral Sclerosis), Autism, Barth syndrome, Complex I Deficiency (NADH dehydrogenase deficiency), Complex II Deficiency (NADH-CoQ reductase deficiency), Complex III Deficiency (Ubiquinone-cytochrome c oxidoreductase deficiency), Complex IV Deficiency/COX Deficiency, Complex V Deficiency (ATP synthase deficiency), CPEO (Chronic Progressive External Ophthalmoplegia Syndrome), Friedreich's ataxia (FRDA or FA), KSS (Kearns-Sayre Syndrome), Lactic Acidosis, Leigh Disease or Syndrome (Subacute Necrotizing Encephalomyelopathy), LHON (Leber's hereditary optic neuropathy), MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Strokelike Episodes), MERRF (Myoclonic Epilepsy and Ragged-Red Fiber Disease), MIDD (Maternally Inherited Diabetes and Deafness), Mitochondrial Myopathy, MNGIE (Myoneurogastointestinal Disorder and Encephalopathy, NARP) (Neuropathy, Ataxia, and Retinitis Pigmentosa), Neurodegenerative disorders associated with Parkinson's, Alzheimer's or Huntington's disease, Pearson Syndrome, Pyruvate Carboxylase Deficiency, Pyruvate Dehydrogenase Deficiency, POLG Mutations ] | ACTIVE | — |
| 044 | [ Analysis of human serum for medical treatment; analysis of human tissues for medical treatment; ] consultancy in the field of cosmetics, namely, consultancy in connection with the selection of cosmetic products and medicated cosmetic products; [ consultancy in the medical field, other than dentistry; drug screening for medical purposes; health care; health care services; ] hygienic and beauty care for human beings or animals; [ medical and surgical diagnostic testing services; medical consultancy in the field of pharmacogenetics; medical consultancy services; medical diagnostic services in the nature of performing diagnosis of diseases; medical services; medical testing for diagnostic or treatment purposes; pharmaceutical consultancy services; ] providing information in connection with all the aforementioned services; rental of ultrasonic diagnostic apparatus [ ; veterinary consultancy services; veterinary services ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Abliva AB
- Other trademarks owned by NeuroVive Pharmaceutical AB
- Other trademarks owned by Pharming Intellectual Property B.V.
- Other trademarks owned by NeuroVive Pharmaceutical AB
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NEUROVIVE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 19, 2026 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jul 28, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 8, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 19, 2023 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Sep 4, 2023 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 7, 2023 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Jan 4, 2023 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Jan 4, 2023 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jan 1, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 16, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Oct 28, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 5, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 17, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 17, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 28, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 23, 2020 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jul 28, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 17, 2020 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 1, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 1, 2020 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 12, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 12, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 22, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 8, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 8, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 8, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 8, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 8, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 29, 2019 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Oct 10, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 10, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 10, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 16, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2019 | ALIE | ASSIGNED TO LIE | — |
| Sep 6, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 6, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 6, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 6, 2019 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Mar 29, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 8, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 7, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 27, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 26, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 13, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 9, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 5, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 31, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |